Turning regulatory content into a signal-rich newsletter

Innolitics is a regulatory consulting firm for medical device software, SaMD submissions, 510(k) pathways, De Novos, and the rest of the FDA surface area. The newsletter is how regulatory specialists, software engineers, and company leaders find Innolitics before an engagement starts.

Before I joined, the newsletter existed but didn't have a system behind it. Articles went out when someone had time, topics were picked from gut feeling, and no one was tracking which content pulled readers into actual submission thinking versus just driving page views.

My role was editorial product end-to-end: taxonomy design, signal-metric instrumentation, cadence calls, and which articles ship. The actual writing was a partnership. I co-wrote some pieces, commissioned others from regulatory specialists on the team, and edited everything against the taxonomy. The decisions that were mine alone: what gets cut, what gets staged for which submission reader, what the conversion funnel looks like. The decisions that were shared: which 510(k) or De Novo example to anchor each piece on, since the regulatory specialists had hands on submissions I hadn't.

The initial assumption was that more frequency would drive more signups. After looking at signup and engagement data, that turned out to be partially true, cadence mattered, but the bigger lever was content taxonomy: what topic families pulled high-intent readers into Class I/II/III submission pathways.

There were no signal metrics. Page views told us what was trafficked, not what was useful. A 510(k) pre-sub deep-dive and a piece of general FDA news were being treated as equivalent in the analytics stack.

The audience is dense and slow-reading. Regulatory specialists, software developers at device companies, Fortune 500 quality leads. They don't have time for marketing noise; they have time for content that saves them an hour on their next submission.

• Re-centered on reader stage, not topic Rather than picking topics from gut feeling, mapped readers by submission stage, early strategy, pre-sub, active submission, post-market. Each stage has different content needs. This became the content taxonomy that drives what we publish.
• Signal metrics over vanity metrics Moved from page views to stage-mapped engagement analytics. Which articles pulled Pre-Sub readers through to Software Validation content? Which De Novo pieces turned into consult requests? Tracked the taxonomy-to-conversion funnel.
• Cadence design, not cadence volume Bimonthly rhythm beats weekly churn for this audience. Regulatory specialists don't have time for noise. Each edition is a curated walk through a slice of the FDA surface area, not a firehose.
• Content deliverables as product Treated software validation guides, AI/ML-enabled SaMD pathway documentation, and 510(k) worked examples as shippable product, not marketing collateral. Each deliverable has acceptance criteria, a signal metric, and a taxonomy slot.
• Editorial + product, bundled Drive a LinkedIn content series alongside the newsletter (product code distinctions like QFM vs. QAS, new K-numbers, warning letter breakdowns). Content and product feed each other: newsletter taxonomy informs 510(k) Browser features; browser-use data informs what we write next.

1. 01Frequency isn't the lever for high-intent audiences. Taxonomy is.
2. 02Page views lie. Stage-mapped engagement doesn't.
3. 03Treat content deliverables like product, acceptance criteria, signal metrics, a taxonomy slot.
4. 04Serialized LinkedIn formats beat one-off posts for 510(k)-shaped audiences. Predictability builds return readers.
5. 05Senior content work is often about saying no to a topic, not yes to another one.
6. 06A regulatory audience reads slowly and remembers. Design for that.
7. 07The strongest pull for this audience: "we have what you're missing." Most readers show up with a good algorithm and no clear idea how to document it for FDA. The newsletter's job, distilled, is to demonstrate that the team has spent the hundreds of hours with reviewers that they haven't, without being a sales pitch. Every piece either teaches a documentation pattern, breaks down a real K-number, or names a misbelief (e.g., that documentation set size scales with feature size, it doesn't; it scales with risk). Conversion happens because the reader recognizes themselves in the gap.

• Innolitics Newsletter↗

  The live newsletter, FDA regulatory intelligence for medical device professionals, delivered bimonthly.